Source comparison
BPC-157 Help Neuropathy Research: Full Comparison
Precede this table: The following comparison evaluates BPC-157 against established neuropathy interventions across mechanism, evidence base, accessibility, and typical response timeline. No current treatment reverses established nerve damage. The goal is slowi
This comparison does not assign a generated winner or score.
- Precede this table: The following comparison evaluates BPC-157 against established neuropathy interventions across mechanism, evidence base, accessibility, and typical response timeline. No current treatment reverses established nerve damage. The goal is slowing progression or partial symptom relief.
- BPC-157
- Promotes axonal regeneration, Schwann cell proliferation, VEGF upregulation
- Preclinical animal models only. No human RCTs
- Research peptide; not FDA-approved; available through compounding sources
- 4–8 weeks in animal models for measurable regeneration
- Promising preclinical data, but absence of human trials limits clinical recommendation
- Gabapentin
- Binds alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release
- Multiple large RCTs; FDA-approved for diabetic neuropathy and postherpetic neuralgia
- Prescription; generic available; insurance coverage standard
- 1–2 weeks for symptomatic relief
- First-line symptomatic treatment. Does not repair nerves, only modulates pain signaling
- Alpha-lipoic acid
- Antioxidant; reduces oxidative stress in nerve tissue
- Meta-analysis of 15 RCTs shows modest benefit in diabetic neuropathy
- OTC supplement; oral and IV formulations
- 3–6 months for symptom improvement
- Modest evidence base; IV administration shows better outcomes than oral
- Physical therapy
- Maintains joint mobility, prevents contractures, stimulates nerve pathways through movement
- Observational studies; standard of care but limited RCT evidence
- Widely available; requires ongoing sessions
- Ongoing. Benefit sustained only with continued therapy
- Essential supportive intervention; does not reverse damage but prevents secondary complications